Tablet Scoring Guidance Could Drop Patient Testing Recommendation
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Advisory Committee for Pharmaceutical Science and Clinical Pharmacology unanimously rejects an idea to test tablet scoring in the relevant patient population, saying there is too much potential variability.
You may also be interested in...
FDA Tablet Scoring Guidance Holds Brands, Generics To Single Standard
Generic and private label industry concerns that scoring conventions could create barriers to market entry did not win out in the agency’s final tablet scoring guidance. FDA advises firms to contact the agency when questions arise about a product’s scoring being patent-protected.
FDA Tablet Scoring Guidance Holds Brands, Generics To Single Standard
Generic and private label industry concerns that scoring conventions could create barriers to market entry did not win out in the agency’s final tablet scoring guidance. FDA advises firms to contact the agency when questions arise about a product’s scoring being patent-protected.
FDA’s Tablet Scoring Final Guidance Requires Generics To Be Same As Brand
Generic industry concerns that scoring conventions could create barriers to entry did not win out in final tablet scoring guidance; FDA says to contact it if the scoring convention is patent protected.